Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IRMD 
Iradimed Co (IRMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: IRMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $71
1 Year Target Price $71
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.41% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 769.39M USD | Price to earnings Ratio 39.04 | 1Y Target Price 71 |
Price to earnings Ratio 39.04 | 1Y Target Price 71 | ||
Volume (30-day avg) 2 | Beta 0.93 | 52 Weeks Range 41.82 - 62.90 | Updated Date 07/2/2025 |
52 Weeks Range 41.82 - 62.90 | Updated Date 07/2/2025 | ||
Dividends yield (FY) 1.13% | Basic EPS (TTM) 1.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 26.33% | Operating Margin (TTM) 27.84% |
Management Effectiveness
Return on Assets (TTM) 14.92% | Return on Equity (TTM) 23.81% |
Valuation
Trailing PE 39.04 | Forward PE 34.36 | Enterprise Value 719246737 | Price to Sales(TTM) 10.24 |
Enterprise Value 719246737 | Price to Sales(TTM) 10.24 | ||
Enterprise Value to Revenue 9.57 | Enterprise Value to EBITDA 30.69 | Shares Outstanding 12715100 | Shares Floating 7161022 |
Shares Outstanding 12715100 | Shares Floating 7161022 | ||
Percent Insiders 36.83 | Percent Institutions 58.81 |
Upturn AI SWOT
Iradimed Co
Company Overview
History and Background
Iradimed Corporation was founded in 1992. It focuses on developing, manufacturing, and distributing innovative MRI-compatible medical devices. The company's early focus was on infusion pumps, later expanding to other MRI-compatible devices.
Core Business Areas
- MRI Products: Develops and markets MRI-compatible IV infusion pumps, patient vital signs monitoring systems, and other related accessories.
- Non-MRI Products: Formerly included commercial products and services, including contract design and manufacturing for non-MRI-related devices, although this area is less emphasized now.
Leadership and Structure
John P. McCorvey serves as the CEO and Chairman. The company has a typical corporate structure with departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- MRidium MRI Infusion Pump System: This is Iradimed's flagship product, an MRI-compatible IV infusion pump. Market share is estimated to be significant in the MRI-compatible infusion pump market, potentially exceeding 50%. Competitors include Medtronic and Smiths Medical, but Iradimed is considered a leader in this niche. Revenue from this product is a substantial portion of the company's total revenue.
- IRadimed 3880 MRI Patient Vital Signs Monitoring System: An MRI-compatible vital signs monitoring system. While market share data is less readily available, it represents a key component of Iradimed's product line. Competitors include Philips Healthcare and GE Healthcare, who also offer MRI compatible monitoring systems.
Market Dynamics
Industry Overview
The market for MRI-compatible devices is driven by the increasing use of MRI in diagnostics and treatment. Growth is fueled by technological advancements and an aging population. There is a focus on patient safety and improved clinical workflows.
Positioning
Iradimed is a niche player specializing in MRI-compatible medical devices. Its competitive advantage lies in its expertise and proprietary technology in this specific area. They hold a strong position with MRI compatible infusion pumps and monitoring systems.
Total Addressable Market (TAM)
The TAM for MRI-compatible devices is estimated to be in the hundreds of millions of dollars annually and growing. Iradimed is well-positioned to capture a significant portion of this TAM due to its focused product line and expertise.
Upturn SWOT Analysis
Strengths
- Specialization in MRI-compatible medical devices
- Strong market position in MRI infusion pumps
- Proprietary technology
- FDA approvals for key products
Weaknesses
- Limited product diversification
- Dependence on a niche market
- Smaller size compared to larger medical device companies
- High customer concentration
Opportunities
- Expanding product line within the MRI environment
- Entering new geographic markets
- Developing strategic partnerships
- Increasing adoption of MRI-guided procedures
Threats
- Increased competition from larger medical device companies
- Technological obsolescence
- Regulatory changes
- Economic downturns impacting hospital budgets
Competitors and Market Share
Key Competitors
- MDSO
- GE
- SIEMENS (OTC)
- PHILIPS (PHG)
Competitive Landscape
Iradimed's advantage is its specialization in MRI-compatible devices. Its disadvantage is its smaller size compared to its competitors like GE and Siemens.
Growth Trajectory and Initiatives
Historical Growth: Iradimed has experienced growth driven by increased demand for MRI-compatible devices.
Future Projections: Analyst estimates generally project continued growth for Iradimed, driven by expansion of MRI-guided procedures and increased adoption of its products. However, this varies and analyst forecasts are not guaranteed.
Recent Initiatives: Recent initiatives include product development, strategic partnerships, and expansion into new markets.
Summary
Iradimed is a specialized medical device company with a strong position in the MRI-compatible infusion pump market. It benefits from increasing use of MRI procedures, but faces challenges related to competition and limited product diversification. Growth projections are generally positive, but success depends on continued innovation and market expansion. The company needs to look out for larger competitors entering their niche and changing regulatory environments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary. Financial performance data is based on historical information and is not a guarantee of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iradimed Co
Exchange NASDAQ | Headquaters Winter Springs, FL, United States | ||
IPO Launch date 2014-07-16 | Founder, Chairman, CEO & President Mr. Roger E. Susi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 160 | Website https://www.iradimed.com |
Full time employees 160 | Website https://www.iradimed.com | ||
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. The company offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. The company was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.